Last reviewed · How we verify
Panzyga, 10% Intravenous Solution
Panzyga is an intravenous immunoglobulin (IVIG) that provides passive immunity by supplying pooled human antibodies to modulate immune responses and reduce inflammation.
Panzyga is an intravenous immunoglobulin (IVIG) that provides passive immunity by supplying pooled human antibodies to modulate immune responses and reduce inflammation. Used for Primary immunodeficiency disorders, Secondary immunodeficiency, Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy).
At a glance
| Generic name | Panzyga, 10% Intravenous Solution |
|---|---|
| Sponsor | Octapharma |
| Drug class | Intravenous Immunoglobulin (IVIG) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As a 10% liquid IVIG preparation, Panzyga contains polyvalent immunoglobulins derived from pooled human plasma that can neutralize pathogens, block pathogenic antibodies, and modulate complement activation and inflammatory cytokine production. It is used in primary and secondary immunodeficiency states as well as autoimmune and inflammatory conditions where immune dysregulation is pathogenic. The mechanism involves both replacement of deficient antibodies and immunomodulatory effects on B cells, T cells, and innate immune pathways.
Approved indications
- Primary immunodeficiency disorders
- Secondary immunodeficiency
- Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy)
Common side effects
- Headache
- Fever
- Chills
- Fatigue
- Infusion site reactions
- Thrombosis
- Aseptic meningitis
Key clinical trials
- Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections (PHASE3)
- Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients (PHASE3)
- Panzyga in CIDP Administered at Different Infusion Rates (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Panzyga, 10% Intravenous Solution CI brief — competitive landscape report
- Panzyga, 10% Intravenous Solution updates RSS · CI watch RSS
- Octapharma portfolio CI